Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. markets close on May 7, 2025, followed by an analyst conference call on May 8, 2025, at 8:00 am EDT (14:00 CET).
The conference call will be accessible via webcast to media, investors, and the public through Alvotech's investor website. The webcast recording will remain available for replay for 90 days after the event.
Alvotech (NASDAQ: ALVO), un'azienda biotecnologica globale specializzata nello sviluppo di farmaci biosimilari, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025. La società pubblicherà i risultati del Q1 2025 dopo la chiusura dei mercati statunitensi il 7 maggio 2025, seguiti da una conference call con gli analisti il 8 maggio 2025, alle 8:00 EDT (14:00 CET).
La conference call sarà accessibile via webcast a media, investitori e pubblico attraverso il sito web per gli investitori di Alvotech. La registrazione del webcast sarà disponibile per la visione in replica per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global centrada en el desarrollo de medicamentos biosimilares, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025. La compañía publicará sus resultados del Q1 2025 después del cierre de los mercados estadounidenses el 7 de mayo de 2025, seguido de una llamada con analistas el 8 de mayo de 2025, a las 8:00 am EDT (14:00 CET).
La llamada se podrá seguir vía webcast para medios, inversores y público a través del sitio web para inversores de Alvotech. La grabación del webcast estará disponible para reproducción durante 90 días después del evento.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품 개발에 주력하는 글로벌 바이오테크 기업으로, 2025년 1분기 재무 실적 발표 일정을 확정했습니다. 회사는 미국 시장 마감 후인 2025년 5월 7일에 2025년 1분기 실적을 발표하며, 이어서 2025년 5월 8일 오전 8시 EDT(오후 2시 CET)에 애널리스트 컨퍼런스 콜을 진행할 예정입니다.
컨퍼런스 콜은 Alvotech 투자자 웹사이트를 통해 미디어, 투자자 및 일반인이 웹캐스트로 참여할 수 있습니다. 웹캐스트 녹화본은 행사 후 90일 동안 다시보기로 제공됩니다.
Alvotech (NASDAQ : ALVO), une entreprise biotechnologique mondiale spécialisée dans le développement de médicaments biosimilaires, a programmé l'annonce de ses résultats financiers du premier trimestre 2025. La société publiera ses résultats du T1 2025 après la fermeture des marchés américains le 7 mai 2025, suivie d'une conférence téléphonique avec les analystes le 8 mai 2025 à 8h00 EDT (14h00 CET).
La conférence téléphonique sera accessible via webcast aux médias, investisseurs et au public via le site investisseur d'Alvotech. L'enregistrement du webcast restera disponible en replay pendant 90 jours après l'événement.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen, das sich auf die Entwicklung von Biosimilars spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 terminiert. Das Unternehmen wird die Ergebnisse für Q1 2025 nach Börsenschluss in den USA am 7. Mai 2025 veröffentlichen, gefolgt von einer Analystenkonferenz am 8. Mai 2025 um 8:00 Uhr EDT (14:00 CET).
Die Konferenz wird über einen Webcast für Medien, Investoren und die Öffentlichkeit über die Investorenseite von Alvotech zugänglich sein. Die Aufzeichnung des Webcasts wird nach der Veranstaltung für 90 Tage zur Wiedergabe verfügbar bleiben.
- None.
- None.
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public.
Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor website https://investors.alvotech.com. Links to access the webcast or sign in number for analysts is found at https://investors.alvotech.com/events/event-details/q1-2025-earnings. The webcast will also be archived and available for replay for 90 days after the event.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
FAQ
When will Alvotech (ALVO) release its Q1 2025 earnings?
What time is Alvotech's Q1 2025 earnings call?
How can investors access Alvotech's Q1 2025 earnings webcast?
How long will Alvotech's Q1 2025 earnings webcast be available for replay?
